Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
Phase 2 Completed
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
Phase 3 Completed
282 enrolled
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
Phase 3 Completed
1 enrolled
Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer
Phase 3 Completed
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
Phase 3 Completed
14 enrolled
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
Phase 3 Completed
51 enrolled 7 charts
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Phase 3 Completed
2,098 enrolled 12 charts
Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma
Phase NA Completed
31 enrolled 5 charts
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
Phase 3 Completed
114 enrolled 10 charts
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
Phase 3 Completed
114 enrolled
DREXNECK
Phase 2 Completed
1 enrolled
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
Phase 2 Completed
239 enrolled 23 charts
Epoetin Alfa in Treating Anemia in Patients With Solid Tumors
Phase 3 Completed
365 enrolled
Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia
Phase 4 Completed
30 enrolled
Effects of Exercise in Combination With Epoetin Alfa
Phase NA Completed
120 enrolled 16 charts
Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
Phase 4 Completed
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
Phase 3 Completed
275 enrolled
Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome
Phase 2 Completed
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
Phase 3 Completed
Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy
Phase NA Completed
109 enrolled 7 charts
Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue
Phase 2 Completed
A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia
Phase 4 Completed
504 enrolled 17 charts
An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation
Phase 3 Completed
51 enrolled
Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy
Phase 2 Completed
186 enrolled
An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.
Phase 2 Completed
310 enrolled
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks
Phase 2 Completed
129 enrolled
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
Phase 2 Completed
115 enrolled
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
Phase 3 Completed
69 enrolled
A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer
Phase 2 Completed
56 enrolled
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
Phase 3 Completed
224 enrolled
A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy
Phase 4 Completed
110 enrolled
Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia
Phase 4 Completed
358 enrolled
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy
Phase 2 Completed
86 enrolled
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug
Phase 2 Completed
72 enrolled
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
Phase 2 Completed
195 enrolled
The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma
Phase 3 Completed
156 enrolled
Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy
Phase 3 Completed
375 enrolled
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
Phase 3 Completed
201 enrolled
A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy
Phase 4 Completed
316 enrolled
A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy
Phase 3 Completed
939 enrolled
Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.
Phase 3 Completed
56 enrolled